1. Home
  2. ICUI vs CPRX Comparison

ICUI vs CPRX Comparison

Compare ICUI & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ICU Medical Inc.

ICUI

ICU Medical Inc.

HOLD

Current Price

$125.89

Market Cap

3.0B

Sector

Health Care

ML Signal

HOLD

Logo Catalyst Pharmaceuticals Inc.

CPRX

Catalyst Pharmaceuticals Inc.

HOLD

Current Price

$31.17

Market Cap

3.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ICUI
CPRX
Founded
1984
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
3.4B
IPO Year
1995
2006

Fundamental Metrics

Financial Performance
Metric
ICUI
CPRX
Price
$125.89
$31.17
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
1
Target Price
$169.00
$35.00
AVG Volume (30 Days)
210.4K
2.3M
Earning Date
05-07-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
100.62
28.24
EPS
1.20
1.68
Revenue
$2,231,262,000.00
$119,072,803.00
Revenue This Year
N/A
$9.20
Revenue Next Year
$4.46
$10.51
P/E Ratio
$4,118.83
$18.54
Revenue Growth
N/A
16.39
52 Week Low
$107.02
$19.05
52 Week High
$160.29
$32.56

Technical Indicators

Market Signals
Indicator
ICUI
CPRX
Relative Strength Index (RSI) 52.97 73.25
Support Level $121.52 $22.41
Resistance Level $133.16 $32.56
Average True Range (ATR) 4.54 1.30
MACD 0.51 0.30
Stochastic Oscillator 68.23 80.10

Price Performance

Historical Comparison
ICUI
CPRX

About ICUI ICU Medical Inc.

ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.

About CPRX Catalyst Pharmaceuticals Inc.

Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.

Share on Social Networks: